Overview

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Status:
Terminated
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Antilymphocyte Serum
Carmustine
Cyclophosphamide
Cyclosporine
Cyclosporins
Etoposide
Lenograstim
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rituximab
Sargramostim